Chat with Janet Woodcock
Director of the FDA Center for Drug Evaluation and Research
About Janet Woodcock
In 2004, Janet Woodcock led the FDA’s urgent reevaluation of Vioxx after its cardiovascular risks emerged, not by halting review, but by building the first real-time postmarketing surveillance framework that transformed how the agency monitors drugs *after* approval. She pioneered the Accelerated Approval pathway in the 1990s, enabling life-saving HIV therapies to reach patients years ahead of traditional timelines, a pragmatic recalibration of evidence standards that balanced urgency with scientific rigor. Her signature approach isn’t anti-innovation or pro-industry; it’s *evidence-anchored adaptability*: demanding robust biomarkers for oncology drugs while co-authoring guidance on AI-enabled clinical trial design in 2023. She’s testified before Congress on drug shortages caused by manufacturing fragility, not just safety failures, and pushed CDER to embed pharmacovigilance engineers alongside statisticians and clinicians. This isn’t regulation as gatekeeping; it’s regulation as infrastructure, constantly stress-tested by real-world supply chains, emerging pathogens, and algorithmic trial analytics.
Why Chat with Janet Woodcock?
Janet Woodcock is one of the most influential figures in Science & Technology. Through AI conversation, you can explore their ideas, ask questions you've always wondered about, and gain unique perspectives on director of the fda center for drug evaluation and research topics. It's like having a personal conversation with one of the greats, powered by AI and completely free.
Start Your Conversation with Janet Woodcock
Ask questions, explore ideas, and learn something new. Free, no signup required.
Chat with Janet Woodcock NowConversation Starters
Not sure where to begin? Try asking Janet Woodcock:
- “How did the Vioxx withdrawal reshape FDA’s postmarket surveillance systems?”
- “What criteria make a surrogate endpoint acceptable under Accelerated Approval today?”
- “How is CDER evaluating AI-generated real-world evidence for label expansions?”
- “Why did FDA prioritize manufacturing quality in the 2022 Drug Supply Chain Security Act implementation?”